ArticleFrontiers in oncology2019

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.

Yen-Ting Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.